DarioHealth Corp. (DRIO) is a leading global digital therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum. The company is headquartered in New York and publicly traded on the NASDAQ stock exchange under the ticker symbol DRIO.
Founded in 2011, DarioHealth's mission is to transform chronic condition management, offering new levels of engagement, adherence, and outcomes. The company leverages a platform-driven approach and user-focused product design to continuously innovate and provide individuals with the right tools to promote health and improve chronic conditions.
Their proprietary platform brings an evidence-based approach that utilizes user data to provide personalized, high-quality interventions and support for individuals throughout their health journey. The platform covers a diverse range of areas, including diabetes management, hypertension, weight management, musculoskeletal disorders, and behavioral health.
DarioHealth Corp.’s flagship product, the Dario Blood Glucose Monitoring System, was initially targeted at the diabetes market. This compact, all-in-one system includes a glucometer, lancing device, and strips, which sync data with a corresponding mobile application. The application helps patients manage their diabetes better by tracking blood sugar levels, medication, physical activity, and carb intake.
DarioHealth's key innovation lies in its data-driven approach, using artificial intelligence to analyze health patterns and suggest behavioral modifications. By incorporating feedback loops and providing real-time, personalized insights and interventions, DarioHealth not only empowers patients to take control of their health but also provides valuable data to healthcare practitioners and insurance companies.
In recent years, DarioHealth has expanded both its product portfolio and its strategic partnerships, working with healthcare providers, insurance companies, and pharmacies. It has also proved its commercial potential and ability to scale its platform globally.
DarioHealth is highly praised for its dedication to improving outcomes for individuals managing chronic conditions and its innovative approach to healthcare. They believe that the best way to treat chronic disease is not just with medication but with comprehensive treatment that engages individuals by offering them manageable exercise, nutrition, and lifestyle changes. This places DarioHealth Corp. at the forefront of the ongoing healthcare revolution towards patient-centered digital therapeutics.
Through its innovative products and services, dedication to user-centered design, and commitment to improving the lives of those living with chronic conditions, DarioHealth Corp. is making a significant impact on the healthcare industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Alliance Global Partners has initiated coverage on DarioHealth Corp (DRIO.O) with a "Buy" rating. The firm has set a target price of $12 for DarioHealth's stock. This news indicates a positive outlook from Alliance Global Partners for the digital health company.
Alliance Global Partners has initiated coverage on DarioHealth (NASDAQ:DRIO) with a "buy" rating and a $12 price target, suggesting a potential 67.13% upside. Despite this, analyst opinions remain mixed, resulting in a consensus "Hold" rating and an average target price of $10 for the digital health company. DarioHealth recently reported a smaller-than-expected quarterly loss of $0.85 per share, though revenue missed estimates, and the company continues to face negative profitability.
DarioHealth Corp. (NASDAQ:DRIO) recently saw its 2026 revenue estimates cut by analysts from US$26m to US$22m, though loss per share forecasts remained stable at US$3.99. This revision suggests a more conservative outlook, with expected sales growth now significantly slower than the industry average. The downgrade, coupled with potential stock dilution, has raised concerns despite an unchanged price target of US$14.50.
DarioHealth Corp. (NASDAQ:DRIO) recently reported its second-quarter results, showing a revenue miss but a smaller-than-expected per-share loss. Analysts have since revised their forecasts, significantly cutting revenue expectations for 2026 while also reducing estimated losses. Despite these adjustments, the consensus price target remains largely unchanged, suggesting that the intrinsic value of the business is not perceived to have dramatically shifted.
DarioHealth Corp. (NASDAQ:DRIO) recently reported its second-quarter results, which saw an 8.5% revenue miss but a 30% smaller per-share loss than anticipated. Analysts have since updated their forecasts, significantly cutting revenue expectations for 2026 while also reducing loss estimates. Despite these adjustments, the consensus price target remained largely unchanged, implying that the business is performing broadly as expected by analysts.